Golden State Equity Partners Neurocrine Biosciences Inc Transaction History
Golden State Equity Partners
- $182 Million
- Q3 2024
A detailed history of Golden State Equity Partners transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Golden State Equity Partners holds 260 shares of NBIX stock, worth $36,254. This represents 0.02% of its overall portfolio holdings.
Number of Shares
260Holding current value
$36,254% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
626Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.98 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.39 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$718 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$359 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$260 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...